Epidemiology of Venous Thrombosis and Pulmonary Embolism

$625,771R01FY2014HLNIH

University Of Minnesota, Minneapolis MN

Investigators

Linked publications & trials

Paper 39649580 Paper 39586830 Paper 39251642 Paper 38838669 Paper 38258344 Paper 38253929 Paper 38245754 Paper 37986948 Paper 37935012 Paper 37923804 Paper 37732181 Paper 37467317 Paper 37390526 Paper 37327218 Paper 37233989 Paper 37128921 Paper 37120436 Paper 36991100 Paper 36960714 Paper 36734224 Paper 36716319 Paper 36579647 Paper 36474045 Paper 36303018 Paper 36194249 Paper 36154123 Paper 35995843 Paper 35862192 Paper 35652341 Paper 35594314 Paper 35552711 Paper 35504910 Paper 35446786 Paper 35293992 Paper 35264566 Paper 35256806 Paper 35183128 Paper 35094551 Paper 35085396 Paper 34951656 Paper 34779012 Paper 34753797 Paper 34732054 Paper 34553764 Paper 34488438 Paper 34465608 Paper 34452645 Paper 34409733 Paper 34245042 Paper 34214102 Paper 34166655 Paper 34165540 Paper 34059833 Paper 34021356 Paper 34002480 Paper 33838163 Paper 33748830 Paper 33663556 Paper 33609530 Paper 33500576 Paper 33472578 Paper 33402679 Paper 33367543 Paper 33057391 Paper 33031748 Paper 32948842 Paper 32693751 Paper 32476561 Paper 32372009 Paper 32193296 Paper 31965569 Paper 31948643 Paper 31883872 Paper 31850638 Paper 31806883 Paper 31680443 Paper 31680049 Paper 31676102 Paper 31473403 Paper 31263056 Paper 31203748 Paper 31155658 Paper 30971107 Paper 30953632 Paper 30803124 Paper 30780167 Paper 30698716 Paper 30659681 Paper 30642921 Paper 30586737 Paper 30487263 Paper 30442082 Paper 30362614 Paper 30296818 Paper 30217807 Paper 30169657 Paper 30168256 Paper 30042098 Paper 30012220 Paper 30007116

Abstract

DESCRIPTION (provided by applicant): Venous thromboembolism (VTE), comprising deep venous thrombosis and pulmonary embolism, is a major contributor to morbidity and mortality in the U.S. We propose a 4-year renewal of the Longitudinal Investigation of Thromboembolism Etiology (LITE), a prospective study of VTE in the Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS) cohorts, comprising 21,680 participants followed for more than two decades. In the previous three project periods, during which 726 VTEs occurred, we successfully identified or clarified, via 55 publications, multiple genetic and non-genetic risk factors for VTE. Especially intriguing GWAS findings relate to the factor XI (F11) and fibrinogen gamma (FGG) regions. We plan to build upon these findings during this continuation, by adding VTE cases, addressing new hypotheses related to risk factors for VTE, and using the information from all project periods to improve understanding of VTE occurrence. Our aims are to: (1) Extend VTE event follow-up in ARIC for six more years, increasing the number of LITE VTE events by 226, to a total of 952. (2) Test the prospective association of incident VTE with novel biomarkers already being measured: Vitamin D markers; measures of liver dysfunction; sickle cell trait; markers of subclinical thyroid dysfunction. (3) Measure plasm levels of factor XI and Y fibrinogen and determine their association with VTE. (4) Conduct a fine mapping study of the F11 and FGG exonic regions in ARIC and CHS whites to identify the likely functional variants underlying our observed associations of these regions with VTE in GWAS. (5) Conduct genetic association analyses in ARIC and CHS whites to identify low frequency variants associated with important plasma intermediate phenotypes (aPTT, von Willebrand factor, FVIII, FXI, and Y fibrinogen), and to evaluate any significant variants for associations wih VTE. This study is designed to provide new information on risk for VTE, with potential implications for prevention and treatment of VTE.

View original record on NIH RePORTER →